 |
BioWorld-International-2010-11-24
BI Hails F-Star's Fcab Platform in Seven-Target Antibody Deal
BI Hails F-Star's Fcab Platform in Seven-Target Antibody Deal
LONDON – Antibody engineering start-up f-star Biotechnologische GmbH landed its first major partnership, agreeing to an €180 million (US$245.4 million)-per-target deal to apply its modular antibody technology to discover antibodies and/or antibody fragments against seven targets nominated by partner Boehringer Ingelheim GmbH. (BioWorld International)